Strategies for immunotherapy of cancer.
Melief
C J
CJ
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, The Netherlands.
Toes
R E
RE
Medema
J P
JP
van der Burg
S H
SH
Ossendorp
F
F
Offringa
R
R
D000276:Adjuvants, Immunologic; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D017951:Antigen Presentation; D015703:Antigens, CD / Q000502:physiology; D000951:Antigens, Neoplasm / Q000276:immunology; D017209:Apoptosis; D019496:Cancer Vaccines / Q000627:therapeutic use; D016207:Cytokines / Q000235:genetics / Q000502:physiology; D004198:Disease Susceptibility; D015316:Genetic Therapy; D006801:Humans; D007108:Immune Tolerance; D007113:Immunity, Innate; D007130:Immunoglobulin Idiotypes / Q000276:immunology; D007153:Immunologic Deficiency Syndromes / Q000150:complications / Q000276:immunology; D007167:Immunotherapy / Q000379:methods*; D016233:Immunotherapy, Active; D016219:Immunotherapy, Adoptive; D008211:Lymphocyte Cooperation; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D051379:Mice; D009363:Neoplasm Proteins / Q000276:immunology; D009369:Neoplasms / Q000209:etiology / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy; D009858:Oncogenic Viruses / Q000276:immunology; D018124:Receptors, Tumor Necrosis Factor / Q000502:physiology; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014412:Tumor Virus Infections / Q000276:immunology
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D016207:Cytokines; D007130:Immunoglobulin Idiotypes; D009363:Neoplasm Proteins; D018124:Receptors, Tumor Necrosis Factor